This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Interferon alfa-2b is under clinicaldevelopment by Center for GeneticEngineering and Biotechnology and currently in Phase II for Genital Warts (Condylomata Acuminata).
CIGB-128 is under clinicaldevelopment by Center for GeneticEngineering and Biotechnology and currently in Phase I for Brain Tumor. It was also under development for the treatment of mycosis fungoides and recurrent or progressive malignant glioma. It is a combination of interferon alfa-2b with interferon gamma.
CIGB-128 is under clinicaldevelopment by Center for GeneticEngineering and Biotechnology and currently in Phase I for Brain Tumor. It was also under development for the treatment of mycosis fungoides and recurrent or progressive malignant glioma. It is a combination of interferon alfa-2b with interferon gamma.
QN-023a is under clinicaldevelopment by Hangzhou Qihan Biotechnology and currently in Phase I for Relapsed Acute Myeloid Leukemia. QN-023a overview QN-023a is under development for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company develops gene-editing organ transplantation technology.
These capabilities comprise cell and exosome geneticengineering for expressing therapeutic targets. In order to offer complete process development, quality control and regulatory services, cGMP manufacturing for pre-clinical and Phase I/II clinical trials, AGC will use its worldwide network.
is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of geneticengineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.
It’s a multifaceted issue and we perhaps need to go beyond our comfort zone in science and clinicaldevelopment to understand what barriers patients are really facing. But I think we’ve never had more tools than we have now in synthetic biology, geneticengineering, enhanced potency design switches and CRISPR.
As a clinician, healthcare administrator, biotech entrepreneur and venture capital investor, Steve’s leadership and breadth of experience in the clinicaldevelopment of cell and gene therapies will be invaluable to PlateletBio as we progress our cell therapy platform into the clinic later this year,” said Sam Rasty, Ph.D.,
Clynes developed several novel therapeutic approaches in cancer and autoimmunity, including DC targeting for cancer vaccines and Syk and JAK mediated inhibition of DCs and T cells in autoimmunity therapy.
Dean A.
These mAbs are already of human origin and functionally optimized for high potency by the donor’s immune system; hence, they technically do not require geneticengineering or further optimization to achieve full functionality. The Company’s pipeline is highlighted below: Aridis’ Pipeline. AR-301 (VAP). AR-101 (HAP).
(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Currently in late-phase clinicaldevelopment, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant.
This will aid clinicaldevelopment and preparation for investigational new drug (IND) and biologics license application (BLA) submissions. The project should also help clinical research sponsors take advantage of various FDA pathways for accelerated review and approval.
At Elasmogen we have been able to capture, using the latest protein and geneticengineering techniques, the immune system of 10,000 shark equivalents in a test-tube. We then screened these for VNAR binders that block viral infection, and are delighted with the outcomes.”
It is also an off-the-shelf therapy, meaning that people do not have to wait for cell collection and geneticengineering before starting treatment, which could be particularly important for patients who are at a high-risk of their disease progressing. A final decision is expected from the European Commission (EC) in the near future.
Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinicaldevelopment and regulatory rigor, as well as their longstanding commitments to patient safety and public health.
Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinicaldevelopment and regulatory rigor, as well as their longstanding commitments to patient safety and public health.
Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”).
The company will offer end-to-end development and manufacturing services for all protein expression systems and viral vectors, both for drug substances and drug products, from preclinical to clinicaldevelopment and commercial production.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content